Literature DB >> 25587968

Coronary heart disease and genetic variants with low phospholipase A2 activity.

Linda M Polfus1, Richard A Gibbs, Eric Boerwinkle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25587968      PMCID： PMC4339029          DOI： 10.1056/NEJMc1409673

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability.

Authors:  Thomas Münzel; Tommaso Gori
Journal:  Eur Heart J       Date:  2009-08-30       Impact factor: 29.983

3.  Darapladib for preventing ischemic events in stable coronary heart disease.

Authors:  Harvey D White; Claes Held; Ralph Stewart; Elizabeth Tarka; Rebekkah Brown; Richard Y Davies; Andrzej Budaj; Robert A Harrington; P Gabriel Steg; Diego Ardissino; Paul W Armstrong; Alvaro Avezum; Philip E Aylward; Alfonso Bryce; Hong Chen; Ming-Fong Chen; Ramon Corbalan; Anthony J Dalby; Nicolas Danchin; Robbert J De Winter; Stefan Denchev; Rafael Diaz; Moses Elisaf; Marcus D Flather; Assen R Goudev; Christopher B Granger; Liliana Grinfeld; Judith S Hochman; Steen Husted; Hyo-Soo Kim; Wolfgang Koenig; Ales Linhart; Eva Lonn; José López-Sendón; Athanasios J Manolis; Emile R Mohler; José C Nicolau; Prem Pais; Alexander Parkhomenko; Terje R Pedersen; Daniel Pella; Marco A Ramos-Corrales; Mikhail Ruda; Mátyás Sereg; Saulat Siddique; Peter Sinnaeve; Peter Smith; Piyamitr Sritara; Henk P Swart; Rody G Sy; Tamio Teramoto; Hung-Fat Tse; David Watson; W Douglas Weaver; Robert Weiss; Margus Viigimaa; Dragos Vinereanu; Junren Zhu; Christopher P Cannon; Lars Wallentin
Journal:  N Engl J Med       Date:  2014-03-30       Impact factor: 91.245

4.  A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

Authors:  Dirk J Blom; Tomas Hala; Michael Bolognese; Michael J Lillestol; Phillip D Toth; Lesley Burgess; Richard Ceska; Eli Roth; Michael J Koren; Christie M Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae B Kim; Rob Scott; Scott M Wasserman; Evan A Stein
Journal:  N Engl J Med       Date:  2014-03-29       Impact factor: 91.245

5.  Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

Authors:  Alexander Thompson; Pei Gao; Lia Orfei; Sarah Watson; Emanuele Di Angelantonio; Stephen Kaptoge; Christie Ballantyne; Christopher P Cannon; Michael Criqui; Mary Cushman; Albert Hofman; Chris Packard; Simon G Thompson; Rory Collins; John Danesh
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321
  5 in total
  20 in total

1.  Using Mendelian Randomization studies to Assess Causality and Identify New Therapeutic Targets in Cardiovascular Medicine.

Authors:  Wei Zhao; Jung-Jin Lee; Asif Rasheed; Danish Saleheen
Journal:  Curr Genet Med Rep       Date:  2016-09-10

Review 2.  Genetics of coronary artery disease: discovery, biology and clinical translation.

Authors:  Amit V Khera; Sekar Kathiresan
Journal:  Nat Rev Genet       Date:  2017-03-13       Impact factor: 53.242

Review 3.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

Review 4.  Genetics-Current and Future Role in the Prevention and Management of Coronary Artery Disease.

Authors:  Robert Roberts
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 5.  Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.

Authors:  Kiran Musunuru; Sekar Kathiresan
Journal:  Circ Res       Date:  2016-02-19       Impact factor: 17.367

6.  Lipoprotein associated phospholipase A2 activity, apolipoprotein C3 loss-of-function variants and cardiovascular disease: The Atherosclerosis Risk In Communities Study.

Authors:  Yashashwi Pokharel; Wensheng Sun; Linda M Polfus; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett; Eric Boerwinkle; Christie M Ballantyne; Ron C Hoogeveen
Journal:  Atherosclerosis       Date:  2015-06-18       Impact factor: 5.162

Review 7.  Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.

Authors:  Michael V Holmes; Mika Ala-Korpela; George Davey Smith
Journal:  Nat Rev Cardiol       Date:  2017-06-01       Impact factor: 32.419

8.  A Causal Network Analysis of the Fatty Acid Metabolome in African-Americans Reveals a Critical Role for Palmitoleate and Margarate.

Authors:  Azam Yazdani; Akram Yazdani; Eric Boerwinkle
Journal:  OMICS       Date:  2016-08

Review 9.  Leveraging human genetics to guide drug target discovery.

Authors:  Nathan O Stitziel; Sekar Kathiresan
Journal:  Trends Cardiovasc Med       Date:  2016-08-26       Impact factor: 6.677

10.  Oxidant/antioxidant status, paraoxonase activity, and lipid profile in plasma of ovariectomized rats under the influence of estrogen, estrogen combined with progesterone, and genistein.

Authors:  Elif Agacayak; Serdar Basaranoglu; Senem Yaman Tunc; Mehmet Sait Icen; Fatih Mehmet Findik; Ibrahim Kaplan; Osman Evliyaoglu; Talip Gul
Journal:  Drug Des Devel Ther       Date:  2015-06-10       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.